US 12,466,891 B2
Bispecific antibody binding to CD40 and GPC3
Yoshiki Sumitomo, Tokyo (JP); and Masayuki Kai, Tokyo (JP)
Assigned to KYOWA KIRIN CO., LTD., Tokyo (JP)
Appl. No. 17/611,344
Filed by Kyowa Kirin Co., Ltd., Tokyo (JP)
PCT Filed May 15, 2020, PCT No. PCT/JP2020/019547
§ 371(c)(1), (2) Date Nov. 15, 2021,
PCT Pub. No. WO2020/230901, PCT Pub. Date Nov. 19, 2020.
Claims priority of application No. 2019-092297 (JP), filed on May 15, 2019.
Prior Publication US 2022/0220216 A1, Jul. 14, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); C12N 15/63 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); C07K 16/303 (2013.01); C07K 16/46 (2013.01); C12N 15/63 (2013.01); G01N 33/574 (2013.01); A61K 2039/505 (2013.01)] 20 Claims
 
1. A bispecific antibody, which comprises an IgG portion comprising a first antigen binding domain, and also comprises a second antigen binding domain, in which the C terminus of a heavy chain of the IgG portion binds to the second antigen binding domain either directly or via a linker,
wherein the first antigen binding domain binds to human CD40 and comprises a VH comprising CDRs 1 to 3 comprising the amino acid sequences of SEQ ID NOs: 16 to 18, respectively, and a VL comprising CDRs 1 to 3 comprising the amino acid sequences of SEQ ID NOs: 11 to 13, respectively, and
wherein the second antigen binding domain binds to human glypican 3 (GPC3) and comprises a VL comprising CDRs 1 to 3 comprising the amino acid sequences of SEQ ID NOs: 11 to 13, respectively, and any one VH selected from the group consisting of the following (1a) to (1g);
(1a) a VH comprising CDRs 1 to 3 comprising the amino acid sequences of SEQ ID NOs: 42 to 44, respectively;
(1b) a VH comprising CDRs 1 to 3 comprising the amino acid sequences of SEQ ID NOs: 47 to 49, respectively;
(1c) a VH comprising CDRs 1 to 3 comprising the amino acid sequences of SEQ ID NOs: 52 to 54, respectively;
(1d) a VH comprising CDRs 1 to 3 comprising the amino acid sequences of SEQ ID NOs: 57 to 59, respectively;
(1e) a VH comprising CDRs 1 to 3 comprising the amino acid sequences of SEQ ID NOs: 62 to 64, respectively;
(1f) a VH comprising CDRs 1 to 3 comprising the amino acid sequences of SEQ ID NOs: 67 to 69, respectively; and
(1g) a VH comprising CDRs 1 to 3 comprising the amino acid sequences of SEQ ID NOs: 72 to 74, respectively.